Can Urinary microRNA Become a Diagnostic-Support Tool for Pancreatic Cancer?

<p>The startup <strong>Craif</strong> has reached a major milestone by completing specimen collection for a clinical trial involving <strong>AI-driven pancreatic cancer diagnostics</strong>. This technology analyzes <strong>microRNA patterns in urine</strong> to distinguish between high-risk patients and those who actually have the disease. Unlike the company&#39;s existing consumer risk-assessment tools, this new program is being developed as a <strong>Software as a Medical Device (SaMD)</strong> intended to assist doctors in making formal clinical decisions. Research suggests that these <strong>urinary biomarkers</strong> can detect early-stage cancer more effectively than traditional blood tests, providing a non-invasive way to guide further medical intervention. The company anticipates applying for <strong>regulatory approval in 2026</strong>, aiming to integrate molecular data into the standard diagnostic workflow for one of the deadliest forms of cancer. This shift represents a transition from general wellness screening to a <strong>validated medical tool</strong> that could streamline how high-risk individuals are managed in clinical settings.</p>